3 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Graybug Vision: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Drug: GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 2 | Completed | Graybug Vision | 56 | 2019-09-26 | 2022-01-19 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion GB-102 - Diabetic Macular Edema, Retina Vein Occlusion | Phase 2 | Completed | Graybug Vision | 21 | 2019-09-11 | 2021-11-22 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Graybug Vision | 32 | 2017-08-29 | 2019-12-20 |
Choroidal Neovascularization (2) · Macular Degeneration (2) · Macular Edema (1)
Sunitinib (3) · aflibercept (2)
United States (3)